Excerpt: L’accord est très positif et nécessaire pour Daiichi Sankyo, a déclaré Tina Banerjee, une analyste en soins de santé qui publie sur la plateforme Smartkarma. Cela renforce les attentes concernant le portefeuille de médicaments oncologiques de Daiichi
boursorama.com • (Opens in a new window) ⧉
Are you a Professional Journalist?
The Smartkarma Press Pass is a special login created exclusively for pre-approved professional journalists. It allows a journalist to access content on the platform and use all the powerful search and discovery functionality available. Journalists can excerpt and quote from the content on Smartkarma to enrich and support their articles.
